Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Woodward Pharma Services LLC Acquires AcipHex Delayed-Release Tablets By: Latest Press Releases from Newswire.com November 01, 2021 at 09:00 AM EDT WIXOM, Mich. - November 1, 2021 - (Newswire.com) Woodward Pharma Services LLC ("Woodward"), a Michigan-based specialty pharmaceutical company focused on acquiring, licensing and commercializing branded and generic products for the U.S. market, has acquired AcipHex® delayed-release tablets from Eisai Co., Ltd. ("Eisai").Under the agreement, Eisai has divested the rights to AcipHex® for the U.S. market to Woodward for an undisclosed fee. Eisai continues to retain its rights in certain regions outside of the U.S., where it is marketed under the brand name Pariet® (rabeprazole sodium).FDA approved in 1999, AcipHex® (rabeprazole sodium) is a proton pump inhibitor (PPI) indicated in adults for:Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)Maintenance of Healing of Erosive or Ulcerative GERDTreatment of Symptomatic GERDHealing of Duodenal UlcersHelicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer RecurrenceTreatment of Pathological Hypersecretory Conditions, including Zollinger-Ellison SyndromeTreatment of Symptomatic GERD in Adolescent Patients 12 years of age and older"Woodward is thrilled to add AcipHex® to its growing portfolio of branded products," said Nirav Patel, President of Woodward. "AcipHex® plays an important role in serving the needs of a large patient population who are prescribed proton pump inhibitors. Over the coming months, we look forward to continuing to educate providers and consumers alike about the benefits of AcipHex®, as well as investing in support programs, outreach initiatives and life cycle management strategies." For more information about AcipHex® please visit www.aciphex.com.About Woodward Pharma Services LLCWoodward Pharma Services LLC is a specialty pharmaceutical company focused on acquiring, licensing, and commercializing branded and generic prescription drugs for the U.S. market. The Company has a diverse portfolio of products distributed across multiple channels. Contact - Nirav Patel, President - nirav.patel@woodwardpharma.com Press Release Service by Newswire.comOriginal Source: Woodward Pharma Services LLC Acquires AcipHex Delayed-Release Tablets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Woodward Pharma Services LLC Acquires AcipHex Delayed-Release Tablets By: Latest Press Releases from Newswire.com November 01, 2021 at 09:00 AM EDT WIXOM, Mich. - November 1, 2021 - (Newswire.com) Woodward Pharma Services LLC ("Woodward"), a Michigan-based specialty pharmaceutical company focused on acquiring, licensing and commercializing branded and generic products for the U.S. market, has acquired AcipHex® delayed-release tablets from Eisai Co., Ltd. ("Eisai").Under the agreement, Eisai has divested the rights to AcipHex® for the U.S. market to Woodward for an undisclosed fee. Eisai continues to retain its rights in certain regions outside of the U.S., where it is marketed under the brand name Pariet® (rabeprazole sodium).FDA approved in 1999, AcipHex® (rabeprazole sodium) is a proton pump inhibitor (PPI) indicated in adults for:Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD)Maintenance of Healing of Erosive or Ulcerative GERDTreatment of Symptomatic GERDHealing of Duodenal UlcersHelicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer RecurrenceTreatment of Pathological Hypersecretory Conditions, including Zollinger-Ellison SyndromeTreatment of Symptomatic GERD in Adolescent Patients 12 years of age and older"Woodward is thrilled to add AcipHex® to its growing portfolio of branded products," said Nirav Patel, President of Woodward. "AcipHex® plays an important role in serving the needs of a large patient population who are prescribed proton pump inhibitors. Over the coming months, we look forward to continuing to educate providers and consumers alike about the benefits of AcipHex®, as well as investing in support programs, outreach initiatives and life cycle management strategies." For more information about AcipHex® please visit www.aciphex.com.About Woodward Pharma Services LLCWoodward Pharma Services LLC is a specialty pharmaceutical company focused on acquiring, licensing, and commercializing branded and generic prescription drugs for the U.S. market. The Company has a diverse portfolio of products distributed across multiple channels. Contact - Nirav Patel, President - nirav.patel@woodwardpharma.com Press Release Service by Newswire.comOriginal Source: Woodward Pharma Services LLC Acquires AcipHex Delayed-Release Tablets